Abstract:Background: Breast cancer has the highest incidence rate and causes the most fatalities among all female cancers worldwide. Triple-negative breast cancer (TNBC) is known for its strong invasiveness and higher rates of recurrence. In this research, we aimed to identify MIR4435-2HG as a promising long non-coding RNA (lncRNA) biomarker and therapeutic target for TNBC. Methods: Utilizing clinicopathological information and transcriptome data from The Cancer Genome Atlas (TCGA) database, we assessed the clinical relevance of MIR4435-2HG in breast cancer through univariate and multivariate COX regression, receiver operating characteristic (ROC) analysis, as well as Kaplan-Meier survival analysis. To investigate the biological role of MIR4435-2HG in TNBC, we conducted gene set enrichment analysis (GSEA), as well as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. Additionally, we constructed and validated a nomogram to predict disease-free survival (DFS). Both the R package "pRRophetic" and the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm were employed to forecast the sensitivity to different therapeutics between the high- and low-MIR4435-2HG groups. We employed single-cell RNA sequencing analysis and tumor microenvironment infiltration analysis to investigate the potential involvement of MIR4435-2HG in the TNBC tumor microenvironment. Cellular biological behaviors were assessed utilizing CCK-8, transwell assays, and wound-healing assays. Furthermore, we performed RNA-seq, qRT-PCR, and western blotting analyses to elucidate and confirm the specific mechanisms underlying the role of MIR4435-2HG in TNBC. Results: In our study, we have identified MIR4435-2HG as a significant diagnostic and prognostic factor for TNBC. We observed that MIR4435-2HG is widely expressed and might have a significant impact on the reshaping of the TNBC tumor microenvironment. Patients with TNBC in the high-MIR4435-2HG group may show reduced sensitivity to cisplatin, doxorubicin, and gemcitabine and have an increased propensity for immune escape. Knockdown of MIR4435-2HG inhibits cancer-associated fibroblasts (CAFs) activation. Notably, MIR4435-2HG predominantly enhances the migratory and invasive capabilities of TNBC cells through the epithelial-mesenchymal transition (EMT) process. Mechanistically, we validated that MIR4435-2HG activates the JNK/c-Jun and p38 non-classical MAPK signaling pathway in TNBC cells. Conclusions: Our findings highlight the significant potential of MIR4435-2HG as a highly promising biomarker for TNBC. Targeting MIR4435-2HG could represent an appealing therapeutic approach for TNBC.

Long Non-Coding RNA TDRG1 Facilitates Cell Proliferation, Migration and Invasion in Breast Cancer Via Targeting Mir-214-5p/clic4 Axis

Long Noncoding RNA SNHG14 Promotes Breast Cancer Cell Proliferation and Invasion Via Sponging Mir-193A-3p

Downregulation of Long Non-Coding RNA MR4435-2HG Suppresses Breast Cancer Progression Via the Wnt/β-catenin Signaling Pathway.

ZGRF1 is Associated with Poor Prognosis in Triple-Negative Breast Cancer and Promotes Cancer Stemness Based on Bioinformatics.

LncRNA TDRG1 Promotes the Proliferation, Migration, and Invasion of Cervical Cancer Cells by Sponging Mir-214-5p to Target SOX4

Long chain non coding TUG 1 regulating lung cancer invasion and proliferation by targeting Mir-300 in A 549 cell line

MicroRNA-34a Inhibition of the TLR Signaling Pathway Via CXCL10 Suppresses Breast Cancer Cell Invasion and Migration.

LncRNA TDRKH-AS1 promotes breast cancer progression via the miR-134-5p/CREB1 axis

A Novel Identified Long Intergenic Noncoding RNA, LINC01574, Contributes to Breast Cancer Deterioration Via the Regulation of Mir-6745/Ttyh3 Axis

Long Non-Coding RNA TUG1 Promotes Cell Proliferation and Metastasis in Human Breast Cancer

LncRNA FLVCR1-AS1 promotes proliferation, migration and activates Wnt/β-catenin pathway through miR-381-3p/CTNNB1 axis in breast cancer

MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation

LINC00514 upregulates CCDC71L to promote cell proliferation, migration and invasion in triple‐negative breast cancer by sponging miR-6504-5p and miR-3139

A novel long non‐coding RNA LINC00524 facilitates invasion and metastasis through interaction with TDP43 in breast cancer

LncRNA TTN-AS1 Regulates miR-524-5p and RRM2 to Promote Breast Cancer Progression

Knockdown of LINC00504 Inhibits the Proliferation and Invasion of Breast Cancer Via the Downregulation of Mir-140-5p

Circ_0000511 Accelerates the Proliferation, Migration and Invasion, and Restrains the Apoptosis of Breast Cancer Cells Through the Mir‑326/taz Axis

MicroRNA-218-5p Accelerates Malignant Behaviors of Breast Cancer Through LRIG1

LINC00668 silencing retards tumorigenesis via sponging miR-518c-3p to regulating WDR1 in triple negative breast cancer

LINC01234 promoted malignant behaviors of breast cancer cells via hsa-miR-30c-2-3p/CCT4/mTOR signaling pathway

LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein.